CIMYM BioSciences Ltd
Ms Yvonne JosephManaging Director
Mr Andrew MackieCorporate Development
Mr Nigel DavisCEO
MediSieve is a London-based medical device therapeutics company developing “magnetic blood filtration”, a revolutionary method of treating blood-borne diseases by removing pathogens, toxins or other targets directly from a patient’s bloodstream. Practically any component can be specifically removed (cytokines, toxins, cells etc.), providing a platform technology that could be used to treat a huge range of blood-borne medical conditions, accessing several billion-dollar global markets. Our initial targets are sepsis, cytokine storms, leukaemia and malaria.
Dr George FrodshamCEO
Mereo BioPharma Group plc
Dr Donald CoppenDirector, Corporate Development
Mr John RichardHead of Corporate Development
PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savings onto patients.
Dr Sam BarkerBD & Alliances
Dr Neil TorbettCBO
Mr David ChildsDirector of Product Supply and Commerical Alliances
Dr Mark SampsonChief Medical Officer
Therakind is a private European pharmaceutical company with the primary objective of increasing the availability of authorised speciality medicines and ensuring that these medicines are both safe and effective.
Therakind creates, develops, and improves paediatric and other speciality medicinal products and has already successfully brought two paediatric medicines and a further speciality medicine to market. An extensive pipeline of products is under development.